Orbimed Advisors LLC Grows Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Orbimed Advisors LLC lifted its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 298,301 shares of the company's stock after purchasing an additional 26,391 shares during the period. Orbimed Advisors LLC owned about 0.55% of Bicara Therapeutics worth $5,196,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its stake in shares of Bicara Therapeutics by 171.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock valued at $37,893,000 after acquiring an additional 1,375,265 shares during the last quarter. Deep Track Capital LP raised its position in Bicara Therapeutics by 151.0% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock valued at $34,840,000 after purchasing an additional 1,203,148 shares during the last quarter. Vanguard Group Inc. raised its position in Bicara Therapeutics by 1,457.9% during the 4th quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock valued at $18,997,000 after purchasing an additional 1,020,528 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $16,549,000. Finally, Acorn Capital Advisors LLC bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth approximately $11,208,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Cantor Fitzgerald restated an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a report on Monday, April 7th. Wedbush reaffirmed an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Wells Fargo & Company initiated coverage on shares of Bicara Therapeutics in a research report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target on the stock. Finally, Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Bicara Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $32.43.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $14.19 on Tuesday. Bicara Therapeutics Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $28.09. The firm's 50-day simple moving average is $12.94 and its two-hundred day simple moving average is $15.46.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). As a group, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.